Increasingly, healthcare stakeholders are looking "post-launch" – the period after the introduction of a medicine into clinical practice – to resolve uncertainty about the value of a medicine. Post-launch value assessment (PVA) aims to ensure scarce healthcare resources are wisely spent by coordinating approaches to reduce budgetary, clinical effectiveness, and utilization uncertainty.
Key thought leaders and decision-makers contributed to the Post-launch Value Assessment Working Group and developed a more rational and effective decision framework to guide evidence generation after the registration of a new medicine. Tapestry is now working with stakeholders to apply this approach in medicine-specific pilots.
Recent Working Group topics:
The final recommendations of the Post-launch Value Assessment Working Group identify how to clarify a medicine's value and maximise health outcomes. They also provide companies with a framework that supports constructive discussion with regulatory and reimbursement decision makers and addresses lingering uncertainty that can be resolved post-launch.
The Post-launch Value Assessment Working Group (PVAWG) convened for its first meeting in London in September 2012. Participants focused on resolving issues surrounding uncertainty about the value of medicines at the time of launch and improving the tools used to gather post-launch evidence. This meeting confirmed the need for and value of a decision framework to guide post-launch value assessment decision-making.
Post-launch Value Assessment Working Group
Chief Executive, Society for Mucopolysaccharide Diseases (MPS Society)